None of the trials examined the effects of the interventions in terms of costs .
AUTHORS ' CONCLUSIONS The included trials did not demonstrate significant differences for most of the outcomes when targeting intensive perioperative glycaemic control compared with conventional glycaemic control in patients with diabetes mellitus .
However , posthoc analysis indicated that intensive glycaemic control was associated with an increased number of patients experiencing hypoglycaemic episodes .
BACKGROUND Patients with diabetes mellitus are at increased risk of postoperative complications .
Data from r and omised clinical trials and meta-analyses point to a potential benefit of intensive glycaemic control , targeting near-normal blood glucose , in patients with hyperglycaemia ( with and without diabetes mellitus ) being su bmi tted to surgical procedures .
However , there is limited evidence concerning this question in patients with diabetes mellitus undergoing surgery .
OBJECTIVES To assess the effects of perioperative glycaemic control for diabetic patients undergoing surgery .
Strict versus liberal target range for perioperative glucose in patients undergoing coronary artery bypass grafting: a prospective randomized controlled trial.
OBJECTIVE The purpose of this study was to test the hypothesis that a liberal blood glucose strategy ( 121 - 180 mg/dL ) is not inferior to a strict blood glucose strategy ( 90 - 120 mg/dL ) for outcomes in patients after first-time isolated coronary artery bypass grafting and is superior for glucose control and target blood glucose management . METHODS A total of 189 patients undergoing coronary artery bypass grafting  were investigated in this prospect i ve r and omized study to compare 2 glucose control strategies on patient perioperative outcomes . Three methods of analyses ( intention to treat , completer , and per protocol ) were conducted . Observed power was robust ( > 80 % ) for significant results . RESULTS The groups were similar on preoperative hemoglobin A(1c ) and number of diabetic patients . The liberal group was found to be noninferior to the strict group for perioperative complications and superior on glucose control and target range management . The liberal group had significantly fewer patients with hypoglycemic events ( < 60 mg/dL ; P < .001 ) , but severe hypoglycemic events ( < 40 mg/dL ) were rare and no group differences were found ( P = .23 ) . These results were found with all 3 methods of analysis except for blood glucose variability , maximum blood glucose , and perioperative atrial fibrillation . CONCLUSIONS This study demonstrated that maintenance of blood glucose in a liberal range after coronary artery bypass grafting led to similar outcomes compared with a strict target range and was superior in glucose control and target range management . On the basis of the results of this study , a target blood glucose range of 121 to 180 mg/dL is recommended for patients after coronary artery bypass grafting as advocated by the Society of Thoracic Surgeons
None of the trials examined the effects of the interventions in terms of costs .
AUTHORS ' CONCLUSIONS The included trials did not demonstrate significant differences for most of the outcomes when targeting intensive perioperative glycaemic control compared with conventional glycaemic control in patients with diabetes mellitus .
However , posthoc analysis indicated that intensive glycaemic control was associated with an increased number of patients experiencing hypoglycaemic episodes .
BACKGROUND Patients with diabetes mellitus are at increased risk of postoperative complications .
Data from r and omised clinical trials and meta-analyses point to a potential benefit of intensive glycaemic control , targeting near-normal blood glucose , in patients with hyperglycaemia ( with and without diabetes mellitus ) being su bmi tted to surgical procedures .
However , there is limited evidence concerning this question in patients with diabetes mellitus undergoing surgery .
OBJECTIVES To assess the effects of perioperative glycaemic control for diabetic patients undergoing surgery .